Fitting algorithms and baseline correction influence the results of non‐invasive in vivo quantitation of 2‐hydroxyglutarate with 1H‐MRS. (20th November 2018) - Wenger, Katharina J.
Abstract : 1 H‐MRS enables non‐invasive detection of 2‐hydroxyglutarate (2‐HG), an oncometabolite accumulating in gliomas carrying mutations in the isocitrate dehydrogenase (IDH) genes. Reliable 2‐HG quantitation requires reproducible post‐processing, deployment of fitting algorithms and quantitation methods. We prospectively enrolled 38 patients with suspected or recently diagnosed gliomas (IDH mutated n = 26). The MRI protocol included a 1 H single voxel PRESS sequence with volumes of usually 8 mL or more (20 × 20 × 20 mm 3 ) at T E = 97 ms and 180° pulse spacing. Our aim was to evaluate the reliability of 2‐HG quantitation comparing two frequently used software tools and their respective options of baseline correction (jMRUI with the time domain methods AQSES and QUEST, and LCModel, which analyzes the frequency domain data). For AQSES, degrees of freedom for baseline correction constrains were varied. For LCModel, baseline correction was obtained with and without correction of the unknown background term (predefined macromolecules, lipids). Tissue concentrations were calculated based on the phantom replacement method. Quantitation of 2‐HG levels showed similar mean 2‐HG tissue concentrations for IDH mutated tumors (2.65mM, range 3.06–2.20) for all methods. Bland–Altman plots (difference plots) did not reveal a systematic bias (fixed bias) for any of the algorithms tested, and we were able to show a significant correlation regarding 2‐HG concentration at the same echo time with few statistical outliers (parametric correlation). However, evaluation of outliers suggested that in vivo quantitation of 2‐HG is affected not only by the fitting domain (time or frequency), but also by the baseline correction, which is a major contributing factor to the result of 2‐HG fitting. Clinical application of 2‐HG quantitation as a prognostic or predictive biomarker, particularly in multicenter trials, requires standardized use of fitting methods and baseline correction procedures. Abstract : Quantitation of 2‐HG levels showed similar mean tissue concentrations for IDH mutated tumors (2.65mM, range 3.06 – 2.20) for all methods. Bland Altman plots did not reveal a systematic bias for any of the algorithms tested. We showed a significant correlation regarding 2‐HG concentration with few statistical outliers. However, evaluation of outliers suggested that in vivo quantitation of 2‐HG is not only affected by analysis domains, but also by baseline correction being a major contributing factor to 2‐HG fit.